Article Text

Download PDFPDF
A smoking cessation programme plus inhaled ipratropium improved survival in asymptomatic airway obstruction

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

 Q In current smokers with asymptomatic airway obstruction, is a smoking cessation programme (SCP) with or without inhaled ipratropium more effective than usual care (UC) for reducing all cause mortality?

Clinical impact ratings GP/FP/Primary care ★★★★★☆☆ IM/Ambulatory care ★★★★★★☆ Respirology ★★★★★★☆


Embedded ImageDesign:

randomised placebo controlled trial (Lung Health Study [LHS]).

Embedded ImageAllocation:

unclear allocation concealment.*

Embedded ImageBlinding:


Embedded ImageFollow up period:

14.5 years.

Embedded ImageSetting:

10 clinical centres in the US and Canada.

Embedded ImageParticipants:

5887 smokers 35–60 years of age (mean age 48 y, 63% men) who had asymptomatic airway obstruction.

Embedded ImageIntervention:

a 10 week SCP that included a strong physician message and 12 two hour group sessions using behaviour modification and nicotine gum, plus either inhaled ipratropium (n = 1961) or a placebo inhaler (n = 1962). …

View Full Text


  • * See glossary.

  • For correspondence: Dr J E Connett, University of Minnesota, Minneapolis, MN, USA.

  • Source of funding: National Heart, Lung, and Blood Institute.

Linked Articles

  • Glossary
    BMJ Publishing Group Ltd